GlassScriptPhysician profile
Cyril Nathaniel
NPI 1972515591
$6,953.06
in general payments reported to CMS, 2019-2025
29 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,446 · 2020: $385 · 2021: $274 · 2022: $1,423 · 2023: $2,820 · 2024: $480 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,310 · Travel and Lodging: $1,009 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,310.31 |
| Travel and Lodging | $1,009.49 |
| Education | $105.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,275.54 | 2022-2024 | Micra, Onyx Frontier, Symplicity G3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $837.46 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $707.93 | 2019-2023 | Emblem Mri S-Icd, S-Icd System Magnet, Latitude Communicator Power Supply |
| Medtronic Vascular, INC. | $396.14 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $380.73 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $317.96 | 2019-2023 | Farxiga |
| Abiomed | $285.33 | 2019-2023 | Impella |
| Janssen Pharmaceuticals, INC | $257.91 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $256.31 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $183.58 | 2022-2023 | Optimizer |
| Edwards Lifesciences Corporation | $179.09 | 2019 | |
| Inari Medical, INC. | $173.64 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $153.82 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $125.67 | 2019-2022 | |
| Cardiovascular Systems INC. | $80.34 | 2022-2023 | Diamondback Coronary |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $43.65 | 2022-2023 | Uptravi, Opsumit |
| Novo Nordisk INC | $39.48 | 2019 | |
| Alnylam Pharmaceuticals INC. | $38.88 | 2025 | Onpattro |
| Cvrx, INC. | $31.84 | 2023 | Barostim Neo System |
| Abbott Laboratories | $29.31 | 2023 | Jot Dx |
| Irhythm Technologies, INC. | $23.58 | 2023 | Zio Xt Patch |
| Pfizer INC. | $20.21 | 2019 | |
| Merck Sharp & Dohme LLC | $18.80 | 2023 | Verquvo |
| Astellas Pharma US INC | $18.29 | 2023 | Lexiscan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.86 | 2025 | Jardiance |
| Stryker Corporation | $16.78 | 2025 | Flowtriever |
| Lexicon Pharmaceuticals, INC. | $16.13 | 2023 | Inpefa |
| Cook Medical LLC | $14.58 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cyril Nathaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.